IL155951A0 - Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer - Google Patents

Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Info

Publication number
IL155951A0
IL155951A0 IL15595101A IL15595101A IL155951A0 IL 155951 A0 IL155951 A0 IL 155951A0 IL 15595101 A IL15595101 A IL 15595101A IL 15595101 A IL15595101 A IL 15595101A IL 155951 A0 IL155951 A0 IL 155951A0
Authority
IL
Israel
Prior art keywords
kiaa
diagnosis
treatment
nucleic acids
prostate cancer
Prior art date
Application number
IL15595101A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL155951A0 publication Critical patent/IL155951A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL15595101A 2000-11-28 2001-11-28 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer IL155951A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25346000P 2000-11-28 2000-11-28
PCT/US2001/044539 WO2002044419A2 (fr) 2000-11-28 2001-11-28 Analyse d'expression d'acides nucleiques kiaa et polypeptides utilises dans le diagnostic et le traitement du cancer de la prostate

Publications (1)

Publication Number Publication Date
IL155951A0 true IL155951A0 (en) 2003-12-23

Family

ID=22960358

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15595101A IL155951A0 (en) 2000-11-28 2001-11-28 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Country Status (14)

Country Link
US (1) US7037652B2 (fr)
EP (2) EP2295606A1 (fr)
JP (2) JP2004526426A (fr)
AU (2) AU2002236503C1 (fr)
BR (1) BR0115728A (fr)
CA (1) CA2429749A1 (fr)
HU (1) HUP0303905A3 (fr)
IL (1) IL155951A0 (fr)
MX (1) MXPA03004637A (fr)
NO (1) NO20032391L (fr)
NZ (1) NZ526617A (fr)
PL (1) PL362606A1 (fr)
WO (1) WO2002044419A2 (fr)
ZA (1) ZA200304998B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032243A1 (en) * 2001-07-25 2005-02-10 Pollack Gary M. Method and apparatus for rapid determination of ligand-protein binding using charcoal adsorption
EP2423684A3 (fr) * 2006-04-21 2012-06-27 Wyeth LLC Analyse de profilage d'expression différentielle des phénotypes de culture cellulaire et utilisations associées
DE102006033167A1 (de) * 2006-07-10 2008-01-24 Gelita Ag Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung eines vernetzenden medizinischen Klebers
KR20080080863A (ko) * 2007-03-02 2008-09-05 (주)젠크로스 Ｋｉａａ０３１７의 세포사멸 조절제로서의 신규한 용도
WO2008157299A2 (fr) * 2007-06-15 2008-12-24 Wyeth Analyse de profil d'expression différentielle de phénotypes de culture cellulaire et ses utilisations
KR100951719B1 (ko) * 2007-10-02 2010-04-07 재단법인서울대학교산학협력재단 세포투과성 펩타이드와 형광표지 자성나노입자의 복합체 및그 용도
US20090186358A1 (en) * 2007-12-21 2009-07-23 Wyeth Pathway Analysis of Cell Culture Phenotypes and Uses Thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5030559A (en) 1986-04-01 1991-07-09 Board Of Regents, The University Of Texas System Methods and compositions for the identification of metastatic human tumors
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5118611A (en) 1988-07-25 1992-06-02 Adeza Biomedical Corporation Adenocarcinoma antigen binding methods and reagents
EP0768377A1 (fr) 1988-09-02 1997-04-16 Protein Engineering Corporation Production et sélection de protéines de liaison diversifiées de recombinaison
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
EP0950707B1 (fr) 1989-07-25 2009-02-18 Cell Genesys, Inc. Recombinaison homologue pour cellules donneuses universelles et hôtes mammifères chimériques
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5393788A (en) 1990-07-10 1995-02-28 Smithkline Beecham Corporation Phenylalkyl oxamides
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5674682A (en) 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
GB9309966D0 (en) 1993-05-14 1993-06-30 Nordion Int Inc Detection of prostrate-specific antigen in breast tumors
US5723302A (en) 1993-05-14 1998-03-03 Nordion International Inc. Detection of prostate-specific antigen in breast tumors
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
EP0760006A1 (fr) 1994-04-15 1997-03-05 The Trustees Of Columbia University In The City Of New York Procede de d'evaluation au niveau moleculaire des stades d'evolution du cancer de la prostate
US5856112A (en) 1994-06-16 1999-01-05 Urocor, Inc. Method for selectively inducing biomarker expression in urologic tumor tissue for diagnosis and treatment thereof
US5543994A (en) * 1995-02-27 1996-08-06 International Rectifier Corporation MOSFET driver with fault reporting outputs
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5633161A (en) 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
AU728186B2 (en) 1996-03-15 2001-01-04 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US5861248A (en) 1996-03-29 1999-01-19 Urocor, Inc. Biomarkers for detection of prostate cancer
CA2744096C (fr) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
US5976838A (en) 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CN1195851C (zh) 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
EP1630235A3 (fr) 1997-02-25 2009-05-27 Corixa Corporation Composés pour l'immunodiagnostic du cancer de la prostate et méthodes pour leurs utilisations
CA2286038A1 (fr) 1997-04-08 1998-10-15 Banyu Pharmaceutical Co., Ltd. Gene associe a la metastase cancereuse
WO1999018210A2 (fr) 1997-10-07 1999-04-15 Corixa Corporation Composes et procedes pour l'immunotherapie et l'immunodiagnostic du cancer de la prostate
CA2308565A1 (fr) 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences pour cibler les cellules metastatiques
US6194186B1 (en) * 1997-11-25 2001-02-27 Incyte Pharmaceuticals, Inc. Human protein kinase and kinase inhibitors
US5945522A (en) 1997-12-22 1999-08-31 Genset Prostate cancer gene
WO1999037811A1 (fr) 1998-01-21 1999-07-29 Urocor, Inc. Marqueurs biochimiques et cibles pour le diagnostic, le pronostic et le traitement des affections de la prostate
US5972615A (en) * 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6075182A (en) * 1998-02-13 2000-06-13 Pioneer Hi-Bred International, Inc. Soybean variety 93B53
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
EP1088072A2 (fr) * 1998-06-22 2001-04-04 Incyte Pharmaceuticals, Inc. Genes associes au cancer de la prostate
TR200100916T2 (fr) 1998-07-14 2002-06-21 Corixa@@Corporation
CA2341518A1 (fr) * 1998-08-27 2000-03-09 Quark Biotech, Inc. Genes regules par l'hypoxie
AU5815699A (en) 1998-09-08 2000-03-27 Urocor, Inc. Prostate specific promoter and regulation of gene expression
WO2000018961A2 (fr) 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate
EP1002862A1 (fr) * 1998-11-12 2000-05-24 Nitsch, Roger M., Prof. Dr. Procédés pour diagnostiquer ou traiter des maladies neurologiques
US6355430B1 (en) * 1998-12-24 2002-03-12 Millennium Pharmaceuticals, Inc. Diagnostic and screening methods employing KIAA0101
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2000065067A2 (fr) * 1999-04-23 2000-11-02 University Of Washington Polynucleotides, polypeptides specifiques a la prostate, et leurs procedes d'utilisation
US7691992B2 (en) * 2000-02-25 2010-04-06 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding the human ALEX1 protein
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
NO20032391L (no) 2003-07-16
JP2004526426A (ja) 2004-09-02
HUP0303905A2 (hu) 2004-03-01
NZ526617A (en) 2004-09-24
CA2429749A1 (fr) 2002-06-06
HUP0303905A3 (en) 2005-11-28
BR0115728A (pt) 2003-09-23
WO2002044419A2 (fr) 2002-06-06
EP2295606A1 (fr) 2011-03-16
JP2009106282A (ja) 2009-05-21
EP1343912A2 (fr) 2003-09-17
NO20032391D0 (no) 2003-05-27
AU2002236503B2 (en) 2007-11-01
ZA200304998B (en) 2004-09-27
US7037652B2 (en) 2006-05-02
PL362606A1 (en) 2004-11-02
AU2002236503C1 (en) 2008-11-13
AU3650302A (en) 2002-06-11
US20020115090A1 (en) 2002-08-22
WO2002044419A3 (fr) 2003-04-03
MXPA03004637A (es) 2003-09-05

Similar Documents

Publication Publication Date Title
IL155952A0 (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP1576130A4 (fr) Acides nucleiques et proteines correspondantes denommees 282p1g3, utiles pour le traitement et la detection du cancer
AU2002318112B2 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
GB9925804D0 (en) Biological materials and method useful in the diagnosis and treatment of diseases
EP1429793A4 (fr) Acide nucleique et proteine correspondante designes par steap-1 utiles dans le traitement et la detection du cancer
GB9917307D0 (en) Improvements in and relating to analysis of DNA
EP1537140A4 (fr) Acide nucleique et proteine correspondante 161p2f10b utiles dans le traitement et le depistage du cancer
AU6502199A (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP1517606A4 (fr) Acide nucleique et proteine correspondante appelee 193p1e1b utile dans le traitement et la detection du cancer
EP1372719A4 (fr) Acide nucleique et proteine correspondante denommes 125p5c8 utiles dans le traitement et la detection de cancers
IL155951A0 (en) Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
IL155953A0 (en) Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU2001285018A1 (en) Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
HUP0303899A3 (en) Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP1573023A4 (fr) Acide nucleique et proteine correspondante nommes 162p1e6 utiles dans la detection et le traitement d'un cancer
EP1539805A4 (fr) Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers
EP1023076A4 (fr) Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer
EP1399174A4 (fr) Acide nucleique et proteine correspondante, appelee 121p1f1, utilisee dans le traitement et le depistage du cancer
EP1499350A4 (fr) Acide nucleique et proteine correspondante appelee 205p1b5 utilises dans le traitement et la detection du cancer
AU2001286541A1 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
GB9917491D0 (en) Biological materials and methods useful in the diagnosis and treastment of diseases
GB9917878D0 (en) Biological materials and methods useful in the diagnosis and treatment of diseases
GB9906217D0 (en) Biological materials and methods useful in the diagnosis and treatment of diseases
GB0205963D0 (en) Biological materials and methods useful in the diagnosis and treatment of diseases
GB0113011D0 (en) Biological materials and methods useful in the diagnosis and treatment of diseases